This headline appeared in one of my medpage articles: " MILAN -- The more than 14,500 cancer specialists and allied healthcare professionals gathered here for the annual meeting of the European Society for Medical Oncology are expecting practice-changing trial reports in at least three clinical areas."
One of those areas is prostate cancer:
"The treatment of prostate cancer may change as well when the results of another late-breaker trial are reported, Stahel said.
In that trial, the investigational drug abiraterone in combination with low-dose prednisone was shown to improve outcomes among patients who were unable to control their disease while being treated with taxane-based therapy for hormone-therapy resistant disease."
My medpage site does not have many articles on PCa and treatment when compared with other illnesses. Always encouraging to see them pop up.